IKT · Inhibikase Therapeutics, Inc.

Track IKT — free

$1.98 -0.02 (-1.00%) At close · Oct 6

Russell 2000 member Rebalance outlook locked

Market Cap

$287.44M

139.54M

Volume · Oct 6 583.84K Avg daily vol (3M) 675.29K

Up next

Next earnings call

Nov 11, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 11, 2026

Q2 2024 earnings call transcript

call held Jun 30, 2024

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$60.64M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-14.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+93.9%

Year over year · more shares

Price change (1Y)

+20.5%

Trailing year

Short interest

13.3%

Latest settlement · 47.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15 · calm Equity put/call 0.57

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +2%

above

Price vs 50-day avg −14%

below

RSI (14) 35

neutral

MACD trend Negative

52-week position 51%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −19%

trailing

6-month return +11%

trailing

YTD return −3%

this year

Relative strength −1%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Accumulating

+1% holders QoQ · +18 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

13.27% of float · ▼ -5.0% MoM · 47.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

105 holders — near 3-yr high, broad support

Squeeze score 73

high risk · 0–100

Fundamentals

Fair

Revenue growth −100%

Y/Y

EPS growth +58%

Y/Y

Free cash flow $-27.8M

Balance sheet $8.8M

net cash

Quant / Vol

risk profile

Very High

Volatility 62%

annualized · 1-yr

Max drawdown −27%

past year

ATR 5.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+2% Bullish

Price vs 50-day avg

−14% Bearish

RSI (14)

35 Neutral

MACD trend

Negative Bearish

52-week position

51% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Accumulating

+1% holders QoQ · +18 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

13.27% of float · ▼ -5.0% MoM · 47.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

105 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $1 Now $2 · 51% Range high $3

vs 200-day avg +2% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
clinical sites initiated for Phase 3 IMPROVE-PAH study	43	Q2 2026	—
country regulatory approvals for Phase 3 IMPROVE-PAH study	26	Q2 2026	—
planned Phase 3 IMPROVE-PAH Part A patient enrollment	140	Phase 3 IMPROVE-PAH study design	—
planned Phase 3 IMPROVE-PAH Part B patient enrollment	346	Phase 3 IMPROVE-PAH study design	—
pre-funded warrants outstanding	42.5M	Q2 2026	—
shares of common stock outstanding	132M	Q2 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
IKT Inhibikase Therapeutics, Inc. this stock	$287.44M	-3.4%	-100.0%	—	13.3%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+10.8%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.3%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+535.7%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

105

% held: 84.5%
Net QoQ: +2.7M sh
Top holder: Sands Capital Alternative…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

18.5M

Days to cover: 47.5d
Change: -970.8K sh

View

Short Volume

Short vol %

46%

As of: Oct 6, 2026

Short Total

View

Fails to Deliver

FTD shares

3.9K

Value: $9.1K
As of: Sep 11, 2026

View

Off-Exchange

Off-exchange %

34.8%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

Net income (FY): $-48.3M
EPS diluted: $-0.49

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 8, 2026
This year: 14

View

Exempt Offerings

Offering

$8.0M

Filed: Jun 4, 2024

View

Earnings & Events

Webcasts

Last webcast

Aug 11, 2026

View

Performance

	5D	20D	120D	MTD	YTD
IKT	-2.0%	-18.5%	+10.6%	-3.7%	-3.4%
SPY	+2.0%	+1.7%	+11.3%	+2.2%	+14.3%
vs SPY	-3.9%	-20.2%	-0.7%	-5.8%	-17.7%

Key facts CIK 1750149 CUSIP 45719W205 13F (30d) 2 filings 2 filers Visit website Investor relations

IKT · Inhibikase Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance